Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing

Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European Union and other jurisdictions. In Spain, the 100% academic anti-CD19 CART-cell product varnimcabtage...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Cibrian, Nuria, Español-Rego, Marta, Pascal, Mariona, Delgado, Julio, Ortiz-Maldonado, Valentín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550897/
https://www.ncbi.nlm.nih.gov/pubmed/36238283
http://dx.doi.org/10.3389/fimmu.2022.1005457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550897/
https://www.ncbi.nlm.nih.gov/pubmed/36238283
http://dx.doi.org/10.3389/fimmu.2022.1005457

Ejemplares similares